CompletedPhase 2

Acute Hip Fracture Study in Patients 65 Years or Greater

United States108 participantsStarted 2015-10-30

Plain-language summary

This is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to investigate the safety, tolerability, and efficacy of VK5211 after 12 weeks of treatment. Males and females ≥65 years old who are ambulatory and recovering from a hip fracture will be eligible for participation 3-7 weeks post-injury.

Who can participate

Age range65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Males or females ≥65 years old who are recovering from a hip fracture (occurring 3-7 weeks prior) with no residual surgical issues will be eligible for participation. Exclusion Criteria: * Pathological fracture (e.g. fracture due to Paget's disease of bone, malignancy, etc.). Fracture due to postmenopausal osteoporosis is not considered pathological for this trial.

What they're measuring

Efficacy in Hip Fracture Patients Confirmed by DXA Scan.

Timeframe: Baseline and Week12

Trial details

NCT IDNCT02578095

SponsorViking Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-11-15

Results submitted2025-10-30

View on ClinicalTrials.gov More Hip Fractures trials